TrialAnnals of the rheumatic diseases2011

Imatinib mesylate (Gleevec) in the treatment of diffuse cutaneous systemic sclerosis: results of a 1-year, phase IIa, single-arm, open-label clinical trial.

Robert F Spiera et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.